Research Analysts Offer Predictions for SABS Q3 Earnings

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Investment analysts at Brookline Capital Management lowered their Q3 2025 earnings estimates for SAB Biotherapeutics in a research note issued on Monday, August 11th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($1.04) for the quarter, down from their prior estimate of ($0.43). The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. Brookline Capital Management also issued estimates for SAB Biotherapeutics’ Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($0.48) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at ($0.44) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Thursday, August 7th. The company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27).

A number of other brokerages also recently commented on SABS. Chardan Capital decreased their price objective on shares of SAB Biotherapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 8th. HC Wainwright decreased their price objective on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd.

SAB Biotherapeutics Stock Up 0.5%

SAB Biotherapeutics stock opened at $2.22 on Thursday. The company has a market cap of $23.11 million, a P/E ratio of -0.56 and a beta of 0.53. SAB Biotherapeutics has a 1-year low of $1.00 and a 1-year high of $6.60. The company has a fifty day simple moving average of $2.14 and a 200 day simple moving average of $1.83. The company has a current ratio of 0.87, a quick ratio of 0.87 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. HB Wealth Management LLC boosted its holdings in shares of SAB Biotherapeutics by 10.9% during the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock worth $358,000 after buying an additional 25,800 shares during the period. Silver Oak Securities Incorporated acquired a new stake in SAB Biotherapeutics in the 1st quarter worth about $30,000. Northern Trust Corp acquired a new stake in SAB Biotherapeutics in the 4th quarter worth about $43,000. Diadema Partners LP acquired a new stake in SAB Biotherapeutics in the 4th quarter worth about $114,000. Finally, Geode Capital Management LLC raised its stake in SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after purchasing an additional 12,692 shares in the last quarter. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.